Prostate cancer progression: a scoping review, pharmacoeconomic assessment, and evaluation of quality of life
Small qualitative sample, reliance on baseline HRQoL without longitudinal adjustment, heterogeneity across studies, and exclusion of nmCRPC treatment costs may limit generalizability and precision.
Authors
- Rute Dinis de Sousa (ORCID: https://orcid.org/0000-0001-9713-0204)
- Susana Santos (ORCID: https://orcid.org/0000-0001-5225-6671)
- Helena Canhão (ORCID: https://orcid.org/0000-0003-1894-4870)
- Ana Maria Rodrigues (ORCID: https://orcid.org/0000-0003-2046-8017)
- André Mansinho
- Miguel Gouveia (ORCID: https://orcid.org/0000-0003-0081-0508)
- Lúıs Gomes (ORCID: https://orcid.org/0000-0003-4299-8270)
- José Ricardo Mariano
- José Santos Dias
- Daniela Mariana Zagalo
Institutions
- University of Lisbon (PT)
- Universidade Católica Portuguesa (PT)
- Hospital Universitário de Santa Maria (BR)
- Prostate Cancer Research (GB)
- Hospital de Santo António (PT)
- Johnson & Johnson (Israel) (IL)
- Hospital Santo António dos Capuchos (PT)
- Hospital de Santa Maria (PT)
- Instituto de Investigação Científica Tropical (PT)
- Universidade Nova de Lisboa (PT)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-10-23
- DOI
- https://doi.org/10.1080/13696998.2025.2578100
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00